Language reconfiguration in bilinguals A study with Huntington's disease patients
Por:
Calabria, M, Perez, JP, Martinez-Horta, S, Horta-Barba, A, Carceller, M, Kulisevsky, J, Costa, A
Publicada:
1 ene 2021
Resumen:
The present study investigated language inhibition and cross-language interference as two possible mechanisms of bilingual language control (BLC) that can be affected by Huntington's disease (HD), a neurodegenerative disease (ND) affecting the striatum. To this aim, the study explored the performance of pre-symptomatic and early-stage HD patients in two experimental tasks meant to elicit cross-language interference and language inhibition, including a Stroop task and a language switching task. The results revealed dissociations between these two mechanisms, indicating that language activation or inhibition is related to HD pathology while cross-language interference is not. Switch costs in HD patients were greater than controls in low-demand control conditions of language switching (longer preparation time), while Stroop effects were similar between the two groups of participants. This result was interpreted as a difficulty in overcoming the excessive inhibition applied to non-target language. The BLC processes related to the striatum and subcortical structures are discussed.
Filiaciones:
Calabria, M:
Pompeu Fabra Univ, Ctr Brain & Cognit, Barcelona, Spain
Perez, JP:
Hosp Santa Creu & Sant Pau, Neurol Dept, Movement Disorders Unit, Barcelona, Spain
Biomed Res Inst IIB St Pau, Barcelona, Spain
Ctr Invest Red Enfermedades Neurodegenerat CIBERN, Madrid, Spain
Inst Salud Carlos III, Madrid, Spain
Autonomous Univ Barcelona, Barcelona, Spain
Martinez-Horta, S:
Hosp Santa Creu & Sant Pau, Neurol Dept, Movement Disorders Unit, Barcelona, Spain
Biomed Res Inst IIB St Pau, Barcelona, Spain
Ctr Invest Red Enfermedades Neurodegenerat CIBERN, Madrid, Spain
Horta-Barba, A:
Hosp Santa Creu & Sant Pau, Neurol Dept, Movement Disorders Unit, Barcelona, Spain
Biomed Res Inst IIB St Pau, Barcelona, Spain
Ctr Invest Red Enfermedades Neurodegenerat CIBERN, Madrid, Spain
Carceller, M:
Autonomous Univ Barcelona, Barcelona, Spain
Hosp Santa Creu & Sant Pau, Psychiat Dept, Barcelona, Spain
Kulisevsky, J:
Hosp Santa Creu & Sant Pau, Neurol Dept, Movement Disorders Unit, Barcelona, Spain
Biomed Res Inst IIB St Pau, Barcelona, Spain
Ctr Invest Red Enfermedades Neurodegenerat CIBERN, Madrid, Spain
Autonomous Univ Barcelona, Barcelona, Spain
Hosp Santa Creu & Sant Pau, Psychiat Dept, Barcelona, Spain
Costa, A:
Pompeu Fabra Univ, Ctr Brain & Cognit, Barcelona, Spain
Biomed Res Inst IIB St Pau, Barcelona, Spain
Green Accepted
|